Longevity medicine · evidence-graded

Healthy aging, measured honestly.

For people who want more healthy years, and for the clinicians who advise them: what drives aging, what has human evidence, and what is still a hypothesis. Findings carry a label.

How to read the labels Established Emerging Tested in trials Hypothesis

What this page is, and what it is not.

I am Julian Douwes, a physician and Chief Medical Officer at St. George Hospital in Bad Aibling, Germany. The hospital, founded in 1991, works in integrative oncology, infectious disease and immunology, and that setting shapes how I think about aging: through the immune system as much as through metabolism.

My approach is easy to state. Start with what has outcome data: activity, blood pressure, lipids, glucose, sleep, vaccination. Measure what you can act on. Treat everything else as an experiment that needs a reason, a way to monitor it and a point at which you stop. Where my view goes beyond the data, I say so and label it.

No age-reversal claims. Nothing here is a prescription or a self-treatment protocol.

Written for

  • Adults in midlife and later who want to stay well and are tired of hype.
  • People living with chronic infection or immune problems who wonder what it means for aging.
  • Physicians and scientists who want the primary sources, linked to PubMed.

How to read the labels

Established
Consistent human data from large cohorts, outcome trials or consensus reviews.
Emerging
Real signals from observational studies, natural experiments or small trials. Causation not settled.
Tested in trials
Randomised trials with hard outcomes, including the ones that failed.
Hypothesis
My reasoning or framework. Plausible, not proven, and marked as such every time.

Findings from mice or cell cultures are always called that.

Twelve processes, three layers.

Established framework

In 2023 López-Otín and colleagues expanded their 2013 framework from nine to twelve hallmarks, adding disabled macroautophagy, chronic inflammation and dysbiosis. To count, a hallmark has to change with age, speed up aging when it is made worse experimentally, and slow aging when it is eased; most of that proof comes from animal models. The three groups describe a rough order: damage first, then responses that turn harmful, then system-wide consequences.

The 12 hallmarks of aging in three groups A ring of twelve numbered segments. Segments 1 to 5 are the primary hallmarks (where damage starts), 6 to 8 the antagonistic hallmarks (responses that turn harmful), and 9 to 12 the integrative hallmarks (system-wide consequences). The full names are listed next to the ring.
The 12 hallmarks of aging as grouped by López-Otín and colleagues (Cell, 2023; PMID 36599349). It is a conceptual map that researchers agree on, not a test panel: several hallmarks have no validated clinical measurement yet.
A fresh green beech leaf next to a dry, brown, weathered one on a linen cloth.
Same tree, different state. Read the full hallmarks guide, with graded interventions for each one.

Infection, immunity and the pace of aging.

Two hallmarks, chronic inflammation and altered intercellular communication, run through the immune system, and the immune system ages too. This is the part of longevity medicine closest to my daily work, so it is also where I am most careful to separate evidence from conviction.

  1. Established

    Consistent human data from large cohorts, trials or consensus reviews.

  2. Emerging

    Real signals from observational data, natural experiments or small trials. Causation not settled.

    EBV and multiple sclerosis

    In more than 10 million young US service members, EBV infection preceded multiple sclerosis and raised its risk about 32-fold. Antibodies that cross-react between EBV and a brain protein suggest a mechanism. This is strong evidence for one disease, not for EBV as a driver of aging in general.

    Bjornevik 2022 (PubMed 35025605)Lanz 2022 (PubMed 35073561)

  3. Tested in trials

    Randomised trials with hard outcomes, including results that did not go the hoped-for way.

    CANTOS and LoDoCo2

    Blocking IL-1β (canakinumab) after a heart attack and low-dose colchicine in chronic coronary disease both reduced cardiovascular events, without lowering cholesterol. The costs were real: more fatal infections with canakinumab and more non-cardiovascular deaths with colchicine. Neither trial tested aging itself.

    Ridker 2017 (PubMed 28845751)Nidorf 2020 (PubMed 32865380)

    VALAD: antivirals did not help

    In early Alzheimer’s disease with herpes simplex antibodies, 78 weeks of high-dose valacyclovir did not slow decline; cognition worsened more than with placebo. Treating a latent virus on the assumption that it drives decline can backfire.

    VALAD, JAMA 2026 (PubMed 41405855)

  4. Hypothesis

    My framework. Labelled, because it goes beyond what has been proven.

    Infection- and immune-mediated aging

    1. Persistent and repeated infectionsCMV, EBV and others, over decades
    2. Immune agingfewer naive T cells, a narrower repertoire
    3. InflammagingIL-6 and CRP drift upward
    4. Some hallmarks speed upsenescence, vascular aging, possibly CHIP

    My working model is that a lifetime of persistent and repeated infections adds to immune aging and inflammaging, and through them may speed up several hallmarks. It is one contributor among many, alongside genes, metabolism, environment and chance. It is not a claim that infection causes aging.

    In practice this means I take vaccination, infection history and immune status seriously when I think about someone’s aging, and that I do not treat latent viruses without a clear indication (see VALAD above). What would test the model: trials in which preventing or controlling an infection changes aging-related outcomes, not just one disease.

Read the full article: infection, immunity and aging Inflammaging, in depth

Start where the outcome data is.

  1. 01

    Foundations Established

    More movement and less sitting go with lower mortality in a dose-response pattern (Ekelund 2019). Short or disturbed sleep is linked to higher inflammatory markers (Irwin 2016). Not smoking, and the vaccinations recommended for your age.

  2. 02

    Medical risk factors Established

    Blood pressure, lipids and glucose treated to guideline targets. In people with heart disease and overweight but no diabetes, semaglutide cut major cardiovascular events by 20% (SELECT 2023); in early Alzheimer’s disease it did not slow decline (Cummings 2026, evoke trials). An approved drug for an approved indication, not a longevity pill.

  3. 03

    The frontier Emerging

    Rapamycin extends lifespan in mice (Harrison 2009). In people, a related mTOR inhibitor improved flu-vaccine responses by about 20% (Mannick 2014), and the 48-week PEARL trial found low-dose rapamycin relatively safe but missed its primary endpoint (PEARL 2025). Senolytics lowered senescence markers in small open studies (Hickson 2019) but did not reduce bone loss in a randomised trial (Farr 2024). These belong in trials or closely monitored care.

Two forearms and hands gripping the wooden handle of a rowing machine in morning light.
The least glamorous lever has the best data.

Measure what you can act on.

Several hallmarks have no validated clinical test yet. A useful longevity work-up favours markers that are repeatable and change decisions.

Actionable today

  • Blood pressure Cheap, repeatable, and treating it changes outcomes.
  • ApoB / LDL cholesterol Atherogenic particle burden with well-defined treatment targets.
  • HbA1c and fasting glucose Glucose control over the past months.
  • hsCRP Cardiovascular risk strata: below 1, 1 to 3, above 3 mg/L. Repeat a high value; any infection raises it. AHA/CDC 2003
  • Fitness and daily activity More movement and less sitting track with lower mortality, dose by dose. Ekelund 2019

Research tools, for now

  • Epigenetic clocks (e.g. DunedinPACE) Promising research biomarkers; not yet shown to guide treatment toward better outcomes. Belsky 2022
  • Senescence and telomere tests No validated clinical test for senescent-cell burden; telomere results vary by method.

The longevity blood panel, explained

Where to go next.

Related areas on this site

Brain health at Douwes Brain Center External site

Douwes Brain Center is the brain-health and neuromodulation centre of Clinicum St. Georg in Bad Aibling. These links leave juliandouwes.com.

Sources first, people second.

Written by Dr. med. univ. Julian Douwes, Chief Medical Officer at St. George Hospital, founded in 1991, with patients from 90+ countries.

  • SourcesSources link to PubMed. Negative and inconvenient results stay on the page.
  • LabelsEstablished, emerging, tested in trials, or hypothesis. Mouse data is called mouse data.
  • Not hereTestimonials or before-and-after stories.
  • Updated

New longevity research, graded.

A short email when a study is worth your attention, with the same labels as this page.

Email only, no medical details needed. Privacy policy.

Topics and all 92 articles

By theme

How aging works 9 Hallmarks, inflammation, autophagy and the biology underneath.
Measuring biological age 9 Blood panels, clocks and biomarkers: what they can and cannot tell you.
Longevity drugs 23 Metformin, rapamycin, senolytics and other drugs studied for aging.
NAD+ and mitochondria 16 Cellular energy, NAD+ precursors and mitochondrial health.
Hormones and metabolic health 5 Hormones, insulin sensitivity and body composition.
Lifestyle levers 19 Sleep, exercise, heat and cold, muscle and daily rhythm.
Brain aging 2 Cognitive protection and brain health.
Peptides, supplements and regeneration 8 Supplements, regenerative approaches and longevity peptides, graded.
More topics 1 Everything else on longevity.

Educational content, not medical advice. Decisions about tests, drugs or supplements belong in a conversation with a physician who knows your history.